



GlaxoSmithKline Pharmaceuticals Limited,
GSK House, Dr. Annie Besant Road, Worli
Mumbai- 400030 (India)

T +91 22 2495 9595
F +91 22 2495 9494
Email: askus@gsk.com

Date: September 19, 2025

Subject: Advisory to Customers.

Warm greetings!

Please be informed that the Government of India has implemented a comprehensive reform package, as recommended during the 56th meeting of the GST Council on September 3rd, 2025. This reform introduces a simplified two-slab structure of 5% and 18%, resulting in rate reductions across various sectors, including pharmaceuticals. The changes aim to benefit the common man and promote ease of doing business for all stakeholders

GSK Pharmaceuticals Limited greatly appreciates the efforts of Government of India to enhance the access of essential goods including drugs to the citizens of India. The change in the GST rate requires a downward revision in the Maximum Retail Price (MRP) of the formulations.

In accordance with the Office Memorandum issued by NPPA vide F.No.12(24)/2021/DP/NPPA/Div. II (Vol.II) - (Part-I) dated 12.09.2025 and 13.09.2025 (Refer Annexure 1), regarding implementation of revision in MRPs due to reduction in GST rates, we have revised the MRPs of our products accordingly. Revised prices are attached herewith (Refer Annexure 2) for your reference and records. The reduction in MRP is aligned with the updated GST structure and is effective from 22nd September 2025

You are requested to kindly:

1. Ensure that the benefit of reduced MRP, arising from the GST revision, is passed on to customers for stocks available with you.
2. Bill all products strictly as per the attached Revised Price List, effective from 22.09.2025, superseding the last shared price list.
3. Communicate this revision to all your customers in the Trade Channel on priority.
4. Please communicate with your retailers to ensure access to the revised price list available at conspicuous place for the reference of consumers.

Additionally, we have also uploaded the revised price list on our website i.e. [Home | GSK India](#) for the benefit of all trade channel partners including Distributors, Retailers, Hospitals and Consumers etc.

We solicit your cooperation in implementing the above.

Thank you for your continued support,

Yours sincerely,
For GlaxoSmithKline Pharmaceuticals Limited

Name: Jai Dawane
Designation: Head – Warehousing & Distribution (India)

Annexure 1

E. No 12(24)/2021/DP/NPPA/Div.II(Vol.II)-Part(I)
Government of India
Ministry of Chemicals & Fertilizers
Department of Pharmaceuticals
National Pharmaceutical Pricing Authority

5th /3rd Floor,
YMCA Cultural Centre Building,
1, Jai Singh Road,
New Delhi – 110 001
Dated: 12.09.2025

OFFICE MEMORANDUM

Subject- Implementation of revision in Maximum Retail Price (MRP) due to reduction in Goods and Service Tax (GST) Rates.

The undersigned is directed to refer to the recent Government decision on rationalization of GST rate structures as recommended in the 56th meeting of GST Council, wherein, *inter-alia*, the Council has recommended reduction in the GST rates on drugs/formulations (including medical devices) effective from 22nd September, 2025. Representations have been received from the manufacturers/marketing companies and industry associations seeking clarification/guidance on issues of implementation.

2. In this regard, following directions are issued-
 - i. The benefit of reduction in GST rates shall be passed on the consumers/patients effective from 22nd September, 2025.
 - ii. All the manufacturers /marketing companies selling drugs/formulations shall revise the MRP of drugs/formulations (including medical devices) accordingly w.e.f. 22nd September, 2025.
 - iii. The manufacturer/marketing companies shall issue revised price list or supplementary price list, in Form V/V1 to the dealers, retailers, State Drug Controllers and the Government reflecting the revised GST rates and Revised MRP.
 - iv. Manufacturer/marketing companies shall take immediate measures to sensitise dealers/retailer/consumers about reduction in GST rates through all possible channels of communication including electronic, print and social media. Industry associations may also release advertisements in leading national newspapers including vernacular newspapers to reach out the dealers/retailers to ensure compliance of revised GST rates w.e.f. 22nd September, 2025.
 - v. It is clarified that recalling, re-labelling or re-stickering on the label of container or pack of stocks released in the market, prior to 22nd September, 2025, is not mandatory, if manufacturer/marketing companies are able to ensure price compliance at the retailer level through measures mentioned above.

- vi. However, the manufacturer/marketing companies who desire to re-label or re-sticker the stock available in the market, may do so in a phased manner so that it does not cause shortage of drugs/formulations (including medical devices) in the market. In this regard CDSCO has already issued necessary directions on 11.09.2025 under Rule 104A of the Drugs and Cosmetics Rules, 1945 (copies enclosed).

Encl: As above


(Rashmi Tahiliani)
Director (Pricing)

To,

All the manufacturers, marketers and associations of drugs/formulations for compliance.

Copy to:

1. PSO to Secretary (Pharma), Government of India
2. Drug Controller General (India)
3. All the Drug Controllers / Food & Drug Administration of all the State / UT Governments.

F. no. 12(24)/2021/DP/NPPA/Div.II (Vol.II)-Part(I)

Government of India
Ministry of Chemicals and Fertilizers
Department of Pharmaceuticals
National Pharmaceuticals Pricing Authority

5th / 3rd floor, YMCA Cultural Centre Building,
1, Jai Singh Road, New Delhi - 110 001

Dated: 13.09.2025


OFFICE MEMORANDUM

Subject: Implementation of revision in maximum retail price (MRP) due to reduction in Goods and Service Tax (GST) rates

Please refer to OM of even number, dated 12.09.2025, conveying directions regarding the above subject.

2. In this regard, the undersigned is directed to convey the following revisions:

Direction in paragraph 2 of OM dated 12.09.2025	Revised direction
iii. The manufacturer/marketing companies shall issue revised price list or supplementary price list, in Form V/VI to the dealers, retailers, State Drug Controllers and the Government reflecting the revised GST rates and Revised MRP.	iii. The manufacturer/marketing companies shall issue revised price list or supplementary price list, in Form V/VI, to the dealers and retailers for display to consumers, and to State Drug Controllers and the Government, reflecting the revised GST rates and Revised MRP.
vi. However, the manufacturer/marketing companies who desire to re-label or re-sticker the stock available in the market, may do so in a phased manner so that it does not cause shortage of drugs/formulations (including medical devices) in the market. In this regard CDSCO has already issued necessary directions on 11.09.2025 under Rule 104A of the Drugs and Cosmetics Rules, 1945 (copies enclosed).	vi. However, while adhering to the directions at i. to iv. above, the manufacturer/marketing companies who desire to re-label or re-sticker the stock available in the market, may do so in a phased manner so that it does not cause shortage of drugs/formulations (including medical devices) in the market. In this regard CDSCO has already issued necessary directions on 11.09.2025 (copies enclosed).


(Sanjay Kumar)
Advisor (Cost)

To,

All the manufacturers, marketers and associations of drugs/formulations, for compliance

Copy to:

1. PSO to Secretary (Pharma), Government of India
2. Drugs Controller General (India)
3. All the Drugs Controllers / Food & Drug Administrations of all the State / UT Governments

Annexure 2

Price list effective 22nd September 2025 post implementation of revised GST rates as recommended during the 56th meeting of the GST Council on September 3rd, 2025

Annexure A: List of products and corresponding MRP (including all taxes) where GST rate is revised from 12% to 5% w.e.f 22nd Sep 25

Annexure B: List of products and corresponding MRP (including all taxes) where GST rate is revised from 12% to Nil rate w.e.f 22nd Sep 25

Annexure C: List of products which were at GST rate of 5% or 18% prior to 22nd September 2025 and there is no change in the GST Rate

Annexure A: List of products and corresponding MRP (including all taxes) where GST rate is revised from 12% to 5% w.e.f 22nd Sep 25

Product Name	Retail pack size	New MRP w.e.f 22-Sep-25 (inclusive of GST @5%) Rs	Old MRP upto 21-Sep-25 (inclusive of GST @12%) Rs
CALPOL TABLETS 500 mg+	15'S	14.26	15.21
CALPOL TABLETS 500 mg+	1000'S	720.05	768.06
CALPOL 650 PLUS	15'S	32.04	34.18
CALPOL 250 mg (SUSPENSION)	60 ML	42.84	45.70
CALPOL 120 mg (SUSPENSION)	60 ML	38.45	41.02
CALPOL PAEDIATRIC DROPS	15 ML	30.98	33.05
ELTROXIN 50 MCG TABLETS - CRSF	120's	114.03	121.63
ELTROXIN 100 MCG TABLETS - CRSF	120's	168.84	180.10
ELTROXIN 125 MCG TABLETS - CRSF	60's	108.32	115.54
ELTROXIN 88 MCG TABLETS - CRSF	60's	105.11	112.12
ELTROXIN 75 MCG TABLETS - CRSF	120's	183.32	195.54
ELTROXIN 25 MCG TABLETS - CRSF	120's	184.60	196.91
ELTROXIN TAB 12.5 MCG	120's	189.72	202.37
ELTROXIN TAB 37.5 MCG	120's	187.86	200.38
LANOXIN TABLETS	10'S	14.18	15.12
ZENTEL SUSPENSION	10 ml	19.11	20.38
ZENTEL TABLETS 400 mg	10's	86.70	92.50
ZOVIRAX 200 MG TABLETS	5'S	40.63	43.34
ZOVIRAX 400 MG TABLETS	10's	145.81	155.54
ZOVIRAX SUSPENSION	100 ML	144.22	153.83
ZYLORIC TABLETS 100 MG	10'S	20.16	21.50
ZYLORIC TABLETS 300 MG	10'S	60.02	64.03
BETNOVATE SKIN CREAM - LAMI	20 g	22.22	23.70
BETNESOL INJECTION	1ml	5.06	5.40
GRISOVIN FP TABLETS 250 MG	10's	18.90	20.16
AUGMENTIN TABLETS 625mg / Duo	10's	195.39	208.42
AUGMENTIN DRY SYRUP Duo	3.3g pdr for 30ml	64.42	68.71
AUGMENTIN I.V. 1200 mg	vial of 1.2g	150.24	160.26
AUGMENTIN I.V. Paediatric	vial of 600mg	108.24	115.46
BETNESOL N E/E DROPS	5 ml	22.59	24.10
BETNESOL ORAL DROPS	15 ml	29.01	30.95
BETNESOL TABLETS	20's	17.53	18.70

Product Name	Retail pack size	New MRP w.e.f 22-Sep-25 (inclusive of GST @5%) Rs	Old MRP upto 21-Sep-25 (inclusive of GST @12%) Rs
BETNESOL FORTE TABLETS	20's	29.11	31.05
BETNOVATE GM SKIN CREAM TP-LAMI	20 g	46.63	49.75
BETNOVATE S SKIN OINTMENT	20 g	45.23	48.25
BETNOVATE C SKIN CREAM	30 g	73.03	77.90
BETNOVATE N SKIN CREAM_LAMI TUBE	25 g	62.67	66.85
CCM TABLETS	40'S	561.56	599.00
Calpol T Tablets	15's	115.73	123.45
Cobadex CZS Tablets	15's	116.43	124.20
FEFOL Z CAPSULES	15's	195.42	208.45
FLUTIBACT SKIN OINTMENT	10 GM	243.51	259.75
FLUTIVATE SKIN CREAM	20 GM	370.31	395.00
FLUTIVATE SKIN OINTMENT	20 GM	218.62	233.20
NEOSPORIN SKIN OINTMENT	30 GM	218.25	232.80
NEOSPORIN ANTIBIOTIC POWDER	10 GM	107.15	114.30
NEOSPORIN EYE/ANTIBIOTIC OINTMENT	10 GM	135.70	144.75
PHEXIN CAPSULES 250mg	10	121.50	129.60
PHEXIN CAPSULES 500mg	10	269.63	287.60
PIRITON EXPECTORANT	100 ML	128.30	136.85
PIRITON EXPECTORANT	460 ML	142.13	151.60
PIRITON CS	100 ML	141.47	150.90
SUPACEF INJECTION 1.5 GM	VIAL	361.87	386.00
SUPACEF INJECTION 250 MG	VIAL	95.58	101.95
SUPACEF INJECTION 750 MG	VIAL	221.91	236.70
T-BACT OINTMENT_Lami	5 GM	108.36	115.58
T-BACT OINTMENT 15G_TP_LAMI	15 GM	325.08	346.75
T-BACT CREAM	10 GM	216.72	231.17
TENOVATE GN CREAM	20 GM	103.59	110.50
ZIMIG 250 MG TABLETS	7's	386.11	411.85
ZOVIRAX 800 MG TABLETS	5'S	201.16	214.57
BECADEXAMIN CAPSULES	60's	115.50	123.20
AUGMENTIN TABLETS 375mg	10's	259.64	276.95
AUGMENTIN TABLETS 1000mg / Duo	10's	620.11	661.45
AUGMENTIN I.V. Paediatric	vial of 300mg	77.06	82.20
AUGMENTIN DDS	30 ML	196.13	209.20
Augmentin ES	50 ML	230.38	245.75
CEFTUM TABLETS 250MG	4	206.34	220.10
CEFTUM TABLETS 500MG	4	219.75	234.41
CEFTUM TABLETS 500MG	10	549.41	586.04
DERMOCALM LOTION	100 ML	279.66	298.30
EUMOSONE M SKIN CREAM	15GM	138.70	147.95
EUMOSONE SKIN CREAM	15GM	114.38	122.00
FLUTIVATE E CREAM	30 GM	414.66	442.30
PHEXIN BD TABLETS 375mg	10	254.34	271.30
PHEXIN BD TABLETS 750mg	10	438.89	468.15
PHEXIN DISPERSIBLE TABLETS	10	241.73	257.85
PHEXIN SUSPENSION	19.2 gm/ 30ml	157.50	168.00
PHEXIN KID TABLETS	10	125.62	134.00
PHEXIN REDISYP SUSPENSION 125 mg	60 ml	138.94	148.20
PHEXIN REDISYP SUSPENSION 250 mg	60 ml	217.55	232.05

Product Name	Retail pack size	New MRP w.e.f 22-Sep-25 (inclusive of GST @5%) Rs	Old MRP upto 21-Sep-25 (inclusive of GST @12%) Rs
TENOVATE M SKIN CREAM	15 GM	136.97	146.10
TENOVATE SKIN CREAM	30 GM	160.92	171.65
TENOVATE OINTMENT	15 GM	112.69	120.20
Zimivir 500	3's	170.48	181.85
Zimivir 1000	3's	273.27	291.50
ZODERM E CREAM	50 GM	321.33	342.75
MENVEO 0.5 ml	Vial	4,030.31	4,299.00
MENVEO VIAL +VIAL 48M IN	Vial	4,432.50	4,728.00
FLIXONASE INNOSPRAY	12 GM	576.88	615.35
TRELEGY ELLIPTA 100/62.5/25MCG	30 dose	2,911.15	3,105.23
Seretide Accuhaler 50/500	1 Accuhaler TM containing 60 Blisters	890.30	949.65
Seretide Accuhaler 50/250	1 Accuhaler TM containing 60 Blisters	739.78	789.10
Oilatum Cream 40gm	1	144.89	154.55
ZEJULA TABLET 100MG 8X7	7	71,795.39	76,581.75
JEMPERLI VIAL 50MG/ML 1X10ML_IN-GSK	Vial	3,90,691.88	4,16,738.00

Annexure B: List of products and corresponding MRP (including all taxes) where GST rate is revised from 12% to Nil rate w.e.f 22nd Sep 25

Product Name	Retail pack size	New MRP w.e.f 22-Sep-25 (inclusive of GST @Nil rate) Rs	Old MRP upto 21-Sep-25 (inclusive of GST @12%) Rs
NUCALA SOLUTION FOR INJECTION AI 100 MG/ML	VIAL	75,668.75	84,749.00
Nucala 100 mg	VIAL	71,297.05	79,852.70

Note Applicable for Annexures A & B:

Please ensure that the benefits from the downward revision of GST rates, as mandated by the GST council, are passed on to consumers. If you have inventory with an MRP that differs from the revised MRPs listed above, you are required to sell these items at the updated downward MRP as computed in the illustration below:

Old GST rate	Old MRP (Rs)	New GST rate	New MRP (Rs)	Reduction in MRP (%)
12%	100	5%	93.75	6.25%
12%	100	Nil	89.29	10.71%

Annexure C: List of products which were at GST rate of 5% or 18% prior to 22nd September 2025 and there is no change in the GST Rate

Product Name	Retail pack size	GST Rate before and after 22 nd Sep 2025	MRP wef 22-Sep-25 Rs	MRP upto 21-Sep-25 Rs
BANOCIDE TABLETS 50 MG	20'S	5%	11.96	11.96
BANOCIDE FORTE TABLETS 100 MG	30'S	5%	53.52	53.52
DAPSONE TABLETS 100 MG	1000'S	5%	437.99	437.99
NEOSPORIN H EAR DROPS	5 ML	5%	92.35	92.35
NEOSPORIN H OINTMENT	5 GM	5%	94.95	94.95
HAVRIX 720	1 Vial	5%	2,528.00	2,528.00
Varilrix	1 D	5%	2,418.00	2,418.00
Boostrix	1 D	5%	1,538.00	1,538.00
BOOSTRIX SLCF 48M IN	1 D	5%	1,538.00	1,538.00
Rotarix	1 dose	5%	912.86	912.86
Synflorix (Pre Filled Syringe)	1 dose	5%	2,599.00	2,599.00
FLUARIX TETRA 0.5 ml NH	PFS	5%	2,385.00	2,385.00
FLUARIX TETRA QIV SLCF IN SH	1	5%	2,499.00	2,499.00
Priorix	1 D	5%	941.00	941.00
Physiogel Hypoallergenic Lotion	100 ml	18%	660.00	660.00
Physiogel AI Cream	50 g	18%	725.00	725.00
Physiogel Hypoallergenic AI lotion	100 ml	18%	730.00	730.00
PHYSIOGEL A.I BODY LOTION	1x400 ML	18%	2,250.00	2,250.00
PHYSIOGEL CLEANSER	1X150ML	18%	551.00	551.00
Physiogel Daily Moisture Therapy Cream	75 gm	18%	740.00	740.00
Infanrix Hexa	1 D	5%	3,735.00	3,735.00
SHINGRIX VIAL + AS01B VIAL IN	1	5%	10,999.00	10,999.00
OILATUM BAR	100 GM	18%	237.85	237.85
OILATUM KIDS BAR	50 GM	18%	151.90	151.90
Oilatum Lotion	100ml	18%	464.20	464.20
Oilatum Emollient	100ml	18%	314.70	314.70